The uptake of recombinant Factor VIII in the Netherlands
Summary. In comparison with other biotechnology substitutions, the adoption of recombinant Factor VIII (rFVIII) has been relatively slow. We sent a postal questionnaire to all Dutch haemophilia patients and haemophilia‐treating physicians, to determine which factors predict whether a patient uses plasma‐derived FVIII (pdFVIII) or rFVIII and to investigate patients’ and doctors' opinions on both products. Fifty‐six per cent of patients received rFVIII. This percentage varied widely between centres. Only one doctor would choose to use pdFVIII if he suffered from haemophilia A himself, and 74% wo... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2002 |
Reihe/Periodikum: | British Journal of Haematology ; volume 119, issue 2, page 332-341 ; ISSN 0007-1048 1365-2141 |
Verlag/Hrsg.: |
Wiley
|
Schlagwörter: | Hematology |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26851132 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1046/j.1365-2141.2002.03903.x |